Stock Market & Financial Investment News

News Breaks March 19, 2013 05:45 EDT SRPT Sarepta initiated with a Buy at Deutsche Bank Deutsche Bank believes Sarepta's treatment for Duchenne Muscular Dystrophy, Eteplirsen, has a better safety profile versus competitor Drisapersen and should receive FDA approval by mid-2015. The firm started Sarepta shares with a Buy rating and $45 price target. News For SRPT From The Last 14 Days Check below for free stories on SRPT the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. May 16, 2013 07:29 EDT SRPT Leerink to host a bus tour Boston Biopharma Bus Tour travels throughout Boston on May 16-17. May 9, 2013 12:21 EDT SRPT Sarepta climbs after saying documents to be submitted this month Subscribe for More Information 07:29 EDT SRPT Sarepta reports Q1 EPS (41c), consensus (62c) Reports Q1 revenue $4.5M, consensus $5.85M. May 7, 2013 13:15 EDT SRPT Options with increasing implied volatility: CVRR SRPT PGH TWO GDI HNZ Subscribe for More Information 08:59 EDT SRPT Sarepta initiates dosing in Phase I study of Marburg virus treatment Subscribe for More Information Sign up for a free trial to see the rest of the stories you've been missing.